2018
LBO-001 A multicenter, randomized, double-blind, PLB-controlled trial of Galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertension
Chalasani N, Garcia-Tsao G, Goodman Z, Lawitz E, Abdelmalek M, Rinella M, Ryan M, Noureddin M, Jue C, Pyko M, Allgood A, Shlevin H, Horton R, Zomer E, Traber P, Loomba R, Tetri B, Sanyal A, Harrison S. LBO-001 A multicenter, randomized, double-blind, PLB-controlled trial of Galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertension. Journal Of Hepatology 2018, 68: s100-s101. DOI: 10.1016/s0168-8278(18)30420-3.Peer-Reviewed Original Research
2003
103 Multicenter randomized placebo-controlled trial of non-selective beta-blockers in the prevention of the complications of portal hypertension: final results and identification of a predictive factor
Groszmann R, Garcia-Tsao G, Makuch R, Bosch J, Escorsel A, Garcia-Pagan J, Grace N, Matloff D, Burroughs A, Patch D. 103 Multicenter randomized placebo-controlled trial of non-selective beta-blockers in the prevention of the complications of portal hypertension: final results and identification of a predictive factor. Hepatology 2003, 38: 206. DOI: 10.1016/s0270-9139(03)80146-5.Peer-Reviewed Original Research